Clover Biopharmaceuticals Ends COVID-19 Vaccine Pact With GlaxoSmithKline

China’s Clover Biopharmaceuticals has ended its partnership with UK-based GlaxoSmithKline (GSK) that aimed to develop a COVID-19 vaccine using GSK’s adjuvant technology.

Instead, Clover is collaborating with Dynavax Technologies and launching a global phase 2/3 trial to assess the efficacy of its S-Trimer vaccine candidate combined with a Dynavax adjuvant.

In December, GSK and Sanofi announced they would delay a phase 2b trial of their adjuvanted COVID-19 vaccine candidate after it produced an insufficient immune response in older patients.